ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

The list of what is on top of our mind is much broader than in the past,” says Christophe Weber, Takeda’s president and CEO, ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer said during an ...

A beverage company thinks like a startup to maintain a closer connection with its customers. That’s the word from a recent episode of MIT’s and BCG’s Me, Myself, and AI, which featured Ronald den ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...